Literature DB >> 31773564

Diagnosis of cardiac sarcoidosis despite negative findings on serial late gadolinium enhancement with cardiac magnetic resonance imaging/18F-fluorodeoxyglucose positron emission tomography examinations.

Toshikazu D Tanaka1, Toshiyuki Nagai2, Tomohisa Nagoshi3, Michihiro Yoshimura3.   

Abstract

We present a case of a 42-year-old Japanese man with ocular and pulmonary sarcoidosis who eventually led to a diagnosis with cardiac sarcoidosis (CS) through endomyocardial biopsy (EMB), despite negative findings on both late gadolinium enhancement with cardiac magnetic resonance (LGE-CMR) imaging and 18F-fluorodeoxyglucose positron emission tomography (FDG-PET). Cardiac sarcoidosis (CS) develops in only 5% of patients with systemic sarcoidosis. Previous studies have reported that CS was found in up to 50% of autopsy series with fatal sarcoidosis, implying that CS is frequently underdiagnosed with potentially life-threatening consequences. Therefore, the diagnostic accuracy and prognostic value of CS are important. Currently, LGE-CMR and FDG-PET play an important role in establishing a diagnosis of CS with high sensitivity. In the presented case, regardless of serial examinations with LGE-CMR and FDG-PET, confirmed diagnosis of CS could not be achieved; ultimately, a definitive diagnosis of CS was obtained through EMB. To the best of our knowledge, this is the first reported case showing the diagnosis of CS despite negative findings on serial LGE-CMR and FDG-PET examinations.

Entities:  

Keywords:  Diagnostic and prognostic application; MRI; PET; Sarcoid heart disease

Mesh:

Substances:

Year:  2019        PMID: 31773564     DOI: 10.1007/s12350-019-01968-6

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN: 1071-3581            Impact factor:   5.952


  2 in total

1.  Identification of cardiac sarcoidosis with (13)N-NH(3)/(18)F-FDG PET.

Authors:  Hiroyuki Yamagishi; Naoya Shirai; Masahiko Takagi; Minoru Yoshiyama; Kaname Akioka; Kazuhide Takeuchi; Junichi Yoshikawa
Journal:  J Nucl Med       Date:  2003-07       Impact factor: 10.057

2.  What is the optimal cardiac screening for asymptomatic transthyretin gene mutation carriers?

Authors:  Sang-Geon Cho; Hyung Yoon Kim; Hee-Seung Bom
Journal:  J Nucl Cardiol       Date:  2019-11-25       Impact factor: 5.952

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.